Linagliptin Medochemie

Linagliptin, the active ingredient in Linagliptin Medochemie, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Medochemie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, either alone or in combination with other antidiabetic agents.

- Type 2 diabetes mellitus: improves blood glucose control when added to diet, exercise and other therapies. - Combination therapy with metformin: provides additional HbA1c reduction beyond metformin alone. - Adjunct to lifestyle modification: supports overall glycaemic management in patients unable to achieve targets with non‑pharmacologic measures alone.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory symptoms. - Headache: transient and usually mild. - Gastrointestinal upset: includes nausea, abdominal pain or diarrhoea. - Dizziness: occasional light‑headedness. - Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.

When prescribing Linagliptin, consider the following precautions.

- Renal impairment: monitor renal function; dose adjustment is generally not required but caution is advised. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Cardiovascular disease: observe for any worsening of heart failure symptoms. - Pregnancy: safety not established; avoid unless potential benefit justifies risk. - Breastfeeding: unknown excretion in milk; consider alternative therapy. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with several medicines; monitor accordingly.

Major Interactions (Avoid): - Strong P‑glycoprotein inhibitors (e.g., cyclosporine): may increase linagliptin plasma concentrations. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin exposure, potentially decreasing efficacy. - Diuretics: may affect blood glucose levels, requiring closer monitoring. - Anticoagulants: occasional reports of altered INR; check coagulation parameters as needed.